Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis

Free Subscription Articles published in PLoS One Retrieve available abstracts of 261 articles: HTML format

Single Articles

January 2023
1. ABUKU VG, Allotey EA, Akonde M
   Clinical and laboratory presentation of first-time antenatal care visits of pregnant women in Ghana, a hospital-based study.
   PLoS One. 2023;18:e0280031.
   PubMed     Abstract available
   
   
   
2. RODRIGUEZ S, Yaya I, Huntingdon B, Juraskova I, et al
   Positive relations between sexual quality of life and satisfaction with healthcare in women living with HIV and/or HCV: Results from a multicountry study.
   PLoS One. 2023;18:e0278054.
   PubMed     Abstract available
   
   
   
3. PRATEDRAT P, Nilyanimit P, Wasitthankasem R, Posuwan N, et al
   Qualitative hepatitis C virus RNA assay identifies active infection with sufficient viral load for treatment among Phetchabun residents in Thailand.
   PLoS One. 2023;18:e0268728.
   PubMed     Abstract available
   
   
   
4. STEINBRINK JM, Miller C, Myers RA, Sanoff S, et al
   Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naive recipients of HCV-infected donor kidneys.
   PLoS One. 2023;18:e0280602.
   PubMed     Abstract available
   
   
   
5. DAVITKOV P, Hoffman K, Falck-Ytter Y, Wilson B, et al
   Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study.
   PLoS One. 2023;18:e0280647.
   PubMed     Abstract available
   
   
   
6. AMBAYE E, Ormago MD, Ali MM
   Sero-prevalence and associated factors of sexually transmitted infections among youth-friendly services Attendees.
   PLoS One. 2023;18:e0279900.
   PubMed     Abstract available
   
   
   
7. SY A, McCabe L, Hudson E, Ansari AM, et al
   Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
   PLoS One. 2023;18:e0280551.
   PubMed     Abstract available
   
   
   
8. WONG WB, Seetasith A, Hung A, Zullig LL, et al
   Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
   PLoS One. 2023;18:e0280570.
   PubMed     Abstract available
   
   
   
9. LANGAT B, Muge EK, Night D, Okoth F, et al
   Sero-prevalence of hepatitis B virus and compliance with hepatitis B vaccination schedules among outpatient clinic attendees in Nairobi.
   PLoS One. 2023;18:e0281256.
   PubMed     Abstract available
   
   
   
10. AGHEMO A, Persico M, D'Ambrosio R, Andreoni M, et al
    Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
    PLoS One. 2023;18:e0280165.
    PubMed     Abstract available
    
    
    
11. ESSAYAGH F, Essayagh T, Essayagh M, Khouchoua M, et al
    Disease burden among migrants in Morocco in 2021: A cross‑sectional study.
    PLoS One. 2023;18:e0281129.
    PubMed     Abstract available
    
    
    
12. WATANABE M, Toyoda H, Kawabata T
    Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer muTASWako g1.
    PLoS One. 2023;18:e0278143.
    PubMed     Abstract available
    
    
    
13. PONNUVEL S, Prakash A, Steve RJ, Doss GP, et al
    Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs.
    PLoS One. 2023;18:e0282013.
    PubMed     Abstract available
    
    
    
14. MATHEW A, Ismael N, Meeds H, Vubil A, et al
    Hepatitis B virus genotypes and drug resistance mutations circulating in blood donors in Beira, Mozambique.
    PLoS One. 2023;18:e0281855.
    PubMed     Abstract available
    
    
    
15. MUSSO RIBEIRO DE OLIVEIRA SOUZ, Lima GR, Miranda AE
    Blood-borne infections and pregnancies among women attending a sexual violence assistance center in Brazil: A 10-year retrospective study.
    PLoS One. 2023;18:e0280419.
    PubMed     Abstract available
    
    
    
16. HACK B, Sanghavi K, Gundapaneni S, Fernandez S, et al
    HCV universal EHR prompt successfully increases screening, highlights potential disparities.
    PLoS One. 2023;18:e0279972.
    PubMed     Abstract available
    
    
    
17. ABIMBOLA TO, Van Handel M, Tie Y, Ouyang L, et al
    Cost-effectiveness of expanded hepatitis A vaccination among adults with diagnosed HIV, United States.
    PLoS One. 2023;18:e0282972.
    PubMed     Abstract available
    
    
    
18. FENG Y, Cui X, Lv J, Yan B, et al
    Deep learning models for hepatitis E incidence prediction leveraging meteorological factors.
    PLoS One. 2023;18:e0282928.
    PubMed     Abstract available
    
    
    
19. ZHANG C, Qu Q, Yao Y, Fan X, et al
    Detection of Hepatitis C virus RNA using a novel hybridization chain reaction method that competitively dampens cascade amplification.
    PLoS One. 2023;18:e0268917.
    PubMed     Abstract available
    
    
    
20. RIDDELL J, Hempenstall A, Nakata Y, Gregson S, et al
    The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management.
    PLoS One. 2023;18:e0284151.
    PubMed     Abstract available
    
    
    
21. AWAN A, Shakik S, Banack HR, Fisman DN, et al
    Hepatitis B and C in individuals with a history of antipsychotic medication use: A population-based evaluation.
    PLoS One. 2023;18:e0284323.
    PubMed     Abstract available
    
    
    
22. TESFU MA, Habtemariam TT, Belay NB
    Risk factors associated with Hepatitis B virus infection among pregnant women attending public hospitals in Addis Ababa, Ethiopia.
    PLoS One. 2023;18:e0284646.
    PubMed     Abstract available
    
    
    
23. CASTRO LS, de Rezende GR, Puga MAM, Bandeira LM, et al
    Hepatitis A virus infection in Brazilian correctional facilities.
    PLoS One. 2023;18:e0283868.
    PubMed     Abstract available
    
    
    
24. YU L, Paski SC, Dodge J, Bambha K, et al
    Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
    PLoS One. 2023;18:e0284739.
    PubMed     Abstract available
    
    
    
25. WEATHERLY M, Trivedi A, Chembrolu R, Gupta S, et al
    Maternal infections in pregnancy and the risk of sudden unexpected infant death in the offspring in the U.S., 2011-2015.
    PLoS One. 2023;18:e0284614.
    PubMed     Abstract available
    
    
    
26. YAKOVCHENKO V, Jacob DA, Rogal SS, Morgan TR, et al
    User experience of a hepatitis c population management dashboard in the Department of Veterans Affairs.
    PLoS One. 2023;18:e0285044.
    PubMed     Abstract available
    
    
    
27. AWASTHI A, Katiyar H, Rungta S, Deep A, et al
    Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naive non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
    PLoS One. 2023;18:e0285725.
    PubMed     Abstract available
    
    
    
28. MOHEBBI A, Ghorbanzadeh T, Naderifar S, Khalaj F, et al
    A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study.
    PLoS One. 2023;18:e0285941.
    PubMed     Abstract available
    
    
    
29. NAING TS, Yee WW, Aung HT, Oo KY, et al
    The feasibility and acceptability of integrating hepatitis C and HIV diagnostic testing on centralized molecular laboratory platforms in Myanmar.
    PLoS One. 2023;18:e0282585.
    PubMed     Abstract available
    
    
    
30. ZANONI BC, Milford C, Sithole K, Mosery N, et al
    High risk injection drug use and uptake of HIV prevention and treatment services among people who inject drugs in KwaZulu-Natal, South Africa.
    PLoS One. 2023;18:e0281030.
    PubMed     Abstract available
    
    
    
31. D FREIRE I, L Fielding K, A J Moore D
    Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
    PLoS One. 2023;18:e0286306.
    PubMed     Abstract available
    
    
    
32. CHAPIN CA, Burn TM, Diamond T, Loomes KM, et al
    Effector memory CD8 T-cells as a novel peripheral blood biomarker for activated T-cell pediatric acute liver failure.
    PLoS One. 2023;18:e0286394.
    PubMed     Abstract available
    
    
    
33. KUMAR A, Mahajan H, Chaturvedi S, Kumar A, et al
    Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study.
    PLoS One. 2023;18:e0287333.
    PubMed     Abstract available
    
    
    
34. GREEN MS, Schwartz N, Peer V
    Sex differences in hepatitis A incidence rates-a multi-year pooled-analysis based on national data from nine high-income countries.
    PLoS One. 2023;18:e0287008.
    PubMed     Abstract available
    
    
    
35. NARTEY YA, Okine R, Seake-Kwawu A, Ghartey G, et al
    Hepatitis C virus seroprevalence, testing, and treatment capacity in public health facilities in Ghana, 2016-2021; A multi-centre cross-sectional study.
    PLoS One. 2023;18:e0287580.
    PubMed     Abstract available
    
    
    
36. ROSS J, Rupasinghe D, Avihingsanon A, Lee MP, et al
    Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020.
    PLoS One. 2023;18:e0287909.
    PubMed     Abstract available
    
    
    
37. MONTEIRO IP, Azzi CFG, Bilibio JP, Monteiro PS, et al
    Prevalence of sexually transmissible infections in adolescents treated in a family planning outpatient clinic for adolescents in the western Amazon.
    PLoS One. 2023;18:e0287633.
    PubMed     Abstract available
    
    
    
38. HANSOONGNERN P, Pratedrat P, Nilyanimit P, Wasitthankasem R, et al
    An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA.
    PLoS One. 2023;18:e0287694.
    PubMed     Abstract available
    
    
    
39. LEE GY, Park K, Lee YS, Kim JH, et al
    Molecular diagnosis of patients with hepatitis A virus infection using amplicon-based nanopore sequencing.
    PLoS One. 2023;18:e0288361.
    PubMed     Abstract available
    
    
    
40. ADUGNA A, Demeke G, Toru M, Tsehay D, et al
    Reduced protective efficacy of hepatitis B vaccine among fully vaccinated children in Ethiopia.
    PLoS One. 2023;18:e0288355.
    PubMed     Abstract available
    
    
    
41. OGUNBAJO A, Brooks M, Oke T, Martinez O, et al
    Hepatitis C (HCV) among Black and Latino sexual minority men (SMM) in the Southern United States: Protocol of a prospective cohort epidemiological study.
    PLoS One. 2023;18:e0288129.
    PubMed     Abstract available
    
    
    
42. NAMBUSI K, Gbolahan A, Maureen SM, Tsholofelo RT, et al
    Youth and healthcare workers' perspectives on the feasibility and acceptability of self-testing for HIV, Hepatitis and Syphilis among young people: Qualitative findings from a pilot study in Gaborone, Botswana.
    PLoS One. 2023;18:e0288971.
    PubMed     Abstract available
    
    
    
43. MAYANJA Y, Rida W, Kimani J, Ssetala A, et al
    Hepatitis B status and associated factors among participants screened for simulated HIV vaccine efficacy trials in Kenya and Uganda.
    PLoS One. 2023;18:e0288604.
    PubMed     Abstract available
    
    
    
44. KRUGER K, Oedingen C, Kautz A, Langenbacher D, et al
    Lifestyle interventions for patients with non-alcoholic steato-hepatitis-Design, rationale and protocol of the study "target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)".
    PLoS One. 2023;18:e0288905.
    PubMed     Abstract available
    
    
    
45. CHU C, Gomes T, Antoniou T, Wong WWL, et al
    The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
    PLoS One. 2023;18:e0284914.
    PubMed     Abstract available
    
    
    
46. ALOYSIA D'COR N, Siddaiah P, Mohapatra S, Dhaded SM, et al
    Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.
    PLoS One. 2023;18:e0284898.
    PubMed     Abstract available
    
    
    
47. NAGARAJA T, Chen L, Balasubramanian A, Groopman JE, et al
    Correction: Activation of the Connective Tissue Growth Factor (CTGF)-Transforming Growth Factor beta 1 (TGF-beta 1) Axis in Hepatitis C Virus-Expressing Hepatocytes.
    PLoS One. 2023;18:e0290786.
    PubMed     Abstract available
    
    
    
48. KIM J, Newcomb CW, Carbonari DM, Torgersen J, et al
    Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016.
    PLoS One. 2023;18:e0290889.
    PubMed     Abstract available
    
    
    
49. THI THU PN, Hoang Van D, Ngo Thi Quynh M, Tran Thi N, et al
    Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study.
    PLoS One. 2023;18:e0290235.
    PubMed     Abstract available
    
    
    
50. SCHULER BA, Bastarache L, Wang J, He J, et al
    Population genetic testing and SERPINA1 sequencing identifies unidentified alpha-1 antitrypsin deficiency alleles and gene-environment interaction with hepatitis C infection.
    PLoS One. 2023;18:e0286469.
    PubMed     Abstract available
    
    
    
51. CHAROENKWAN P, Waramit S, Chumnanpuen P, Schaduangrat N, et al
    TROLLOPE: A novel sequence-based stacked approach for the accelerated discovery of linear T-cell epitopes of hepatitis C virus.
    PLoS One. 2023;18:e0290538.
    PubMed     Abstract available
    
    
    
52. SCHWARZ M, Schwarz C, Burghart L, Pfisterer N, et al
    Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes.
    PLoS One. 2023;18:e0290352.
    PubMed     Abstract available
    
    
    
53. EJAZ S, Paracha RZ, Ejaz S, Jamal Z, et al
    Antibody designing against IIIabc junction (JIIIabc) of HCV IRES through affinity maturation; RNA-Antibody docking and interaction analysis.
    PLoS One. 2023;18:e0291213.
    PubMed     Abstract available
    
    
    
54. YOSHIDA Y, Atsukawa M, Kondo C, Kitamura M, et al
    A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.
    PLoS One. 2023;18:e0292019.
    PubMed     Abstract available
    
    
    
55. ZHANG Z, Liang G, Chang K
    Stationary distribution of a reaction-diffusion hepatitis B virus infection model driven by the Ornstein-Uhlenbeck process.
    PLoS One. 2023;18:e0292073.
    PubMed     Abstract available
    
    
    
56. 
    Expression of Concern: The HBx Oncoprotein of Hepatitis B Virus Deregulates the Cell Cycle by Promoting the Intracellular Accumulation and Re-Compartmentalization of the Cellular Deubiquitinase USP37.
    PLoS One. 2023;18:e0293102.
    PubMed    
    
    
    
57. BEDASSA BB, Ebo GG, Yimam JA, Tura JB, et al
    Correction: Prevalence and factors associated with hepatitis B and C virus infections among female Sex workers in Ethiopia: Results of the national biobehavioral Survey, 2020.
    PLoS One. 2023;18:e0292824.
    PubMed     Abstract available
    
    
    
58. GOINS EC, Wein LE, Watkins VY, Campbell AIK, et al
    Maternal and neonatal outcomes in patients with hepatitis C and intrahepatic cholestasis of pregnancy: The sum of the parts.
    PLoS One. 2023;18:e0293030.
    PubMed     Abstract available
    
    
    
59. HOOD RB, Miller WC, Shoben A, Harris RE, et al
    Maternal hepatitis C virus infection and three adverse maternal outcomes in the United States.
    PLoS One. 2023;18:e0291994.
    PubMed     Abstract available
    
    
    
60. BUTT AIK, Imran M, Aslam J, Batool S, et al
    Computational analysis of control of hepatitis B virus disease through vaccination and treatment strategies.
    PLoS One. 2023;18:e0288024.
    PubMed     Abstract available
    
    
    
61. GNANAPANDITHAN K, Ghali MP
    Self-awareness of hepatitis C infection in the United States: A cross-sectional study based on the National Health Nutrition and Examination Survey.
    PLoS One. 2023;18:e0293315.
    PubMed     Abstract available
    
    
    
62. ANGELO L, Vaillant A, Blanchet M, Labonte P, et al
    Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen.
    PLoS One. 2023;18:e0293167.
    PubMed     Abstract available
    
    
    
63. NAQID IA, Mosa AA, Ibrahim SV, Ibrahim NH, et al
    Hepatitis B vaccination status and knowledge, attitude, and practice towards Hepatitis B virus among medical sciences students: A cross-sectional study.
    PLoS One. 2023;18:e0293822.
    PubMed     Abstract available
    
    
    
64. SAGOE KWC, Atuahene K, Ayiku ANA, Pappoe-Ashong PJ, et al
    Hepatitis B and human immunodeficiency virus infections within correctional facilities in Ghana.
    PLoS One. 2023;18:e0293009.
    PubMed     Abstract available
    
    
    
65. LANGAT BK, Ochwedo KO, Borlang J, Osiowy C, et al
    Genetic diversity, haplotype analysis, and prevalence of Hepatitis B virus MHR mutations among isolates from Kenyan blood donors.
    PLoS One. 2023;18:e0291378.
    PubMed     Abstract available
    
    
    
66. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Correction: Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2023;18:e0295455.
    PubMed     Abstract available
    
    
    
67. FONGWEN NT, Nchafack A, Rohan H, Ong JJ, et al
    Role and effectiveness of telephone hotlines in outbreak response in Africa: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0292085.
    PubMed     Abstract available
    
    
    
68. QI M, Santos H, Pinheiro P, McGuinness DL, et al
    Demographic and socioeconomic determinants of access to care: A subgroup disparity analysis using new equity-focused measurements.
    PLoS One. 2023;18:e0290692.
    PubMed     Abstract available
    
    
    January 2022
69. MAWATARI S, Kumagai K, Oda K, Tabu K, et al
    Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
    PLoS One. 2022;17:e0262267.
    PubMed     Abstract available
    
    
    
70. BOODRAM B, Mackesy-Amiti ME, Khanna A, Brickman B, et al
    People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination.
    PLoS One. 2022;17:e0248850.
    PubMed     Abstract available
    
    
    
71. SUZUKI K, Suda G, Yamamoto Y, Abiko S, et al
    Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    PLoS One. 2022;17:e0261760.
    PubMed     Abstract available
    
    
    
72. MBAGA DS, Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, et al
    Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.
    PLoS One. 2022;17:e0262903.
    PubMed     Abstract available
    
    
    
73. BALIASHVILI D, Averhoff F, Kasradze A, Salyer SJ, et al
    Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.
    PLoS One. 2022;17:e0262935.
    PubMed     Abstract available
    
    
    
74. OCAN M, Acheng F, Otike C, Beinomugisha J, et al
    Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda.
    PLoS One. 2022;17:e0262126.
    PubMed     Abstract available
    
    
    
75. MORSICA G, Galli L, Messina E, Castagna A, et al
    Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
    PLoS One. 2022;17:e0262917.
    PubMed     Abstract available
    
    
    
76. JOLLY PE, Akinyemiju TF, Sakhuja S, Sheth R, et al
    Association of aflatoxin B1 levels with mean CD4 cell count and uptake of ART among HIV infected patients: A prospective study.
    PLoS One. 2022;17:e0260873.
    PubMed     Abstract available
    
    
    
77. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2022;17:e0263654.
    PubMed     Abstract available
    
    
    
78. LAMORI J, Feng X, Pericone CD, Mesa-Frias M, et al
    Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults.
    PLoS One. 2022;17:e0264062.
    PubMed     Abstract available
    
    
    
79. NAGURA Y, Matsuura K, Iio E, Fujita K, et al
    Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
    PLoS One. 2022;17:e0263844.
    PubMed     Abstract available
    
    
    
80. DESTREMPES F, Gesnik M, Chayer B, Roy-Cardinal MH, et al
    Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease.
    PLoS One. 2022;17:e0262291.
    PubMed     Abstract available
    
    
    
81. KHAN M, Khan S, Gondal MF, Bibi S, et al
    Genetic diversity in enhancer II region of HBV genotype D and its association with advanced liver diseases.
    PLoS One. 2022;17:e0261721.
    PubMed     Abstract available
    
    
    
82. NAGORNYKH AM, Tyumentseva MA, Tyumentsev AI, Akimkin VG, et al
    Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.
    PLoS One. 2022;17:e0264266.
    PubMed     Abstract available
    
    
    
83. LIM SH, Lee S, Lee YB, Lee CH, et al
    Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262990.
    PubMed     Abstract available
    
    
    
84. ANTUAMWINE BB, Herchel ED, Bawa EM
    Comparative prevalence of hepatitis B virus infection among pregnant women accessing free maternal care in a tertiary hospital in Ghana.
    PLoS One. 2022;17:e0263651.
    PubMed     Abstract available
    
    
    
85. SHRESTHA LB, Yadav GK, Pradhan S, Sharma A, et al
    Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal.
    PLoS One. 2022;17:e0264791.
    PubMed     Abstract available
    
    
    
86. TAHERKHANI R, Farshadpour F
    Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.
    PLoS One. 2022;17:e0265063.
    PubMed     Abstract available
    
    
    
87. TATARA E, Gutfraind A, Collier NT, Echevarria D, et al
    Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    PLoS One. 2022;17:e0264983.
    PubMed     Abstract available
    
    
    
88. TRAN L, Jung J, Feldman R, Riley T 3rd, et al
    Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.
    PLoS One. 2022;17:e0263913.
    PubMed     Abstract available
    
    
    
89. TAKAURA K, Kurosaki M, Inada K, Kirino S, et al
    The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
    PLoS One. 2022;17:e0264075.
    PubMed     Abstract available
    
    
    
90. LIN MC, Dai CY, Huang CF, Yeh ML, et al
    Itemization difference of patient-reported outcome in patients with chronic liver disease.
    PLoS One. 2022;17:e0264348.
    PubMed     Abstract available
    
    
    
91. UCHIDA Y, Nakao M, Yamada S, Tsuji S, et al
    Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
    PLoS One. 2022;17:e0262764.
    PubMed     Abstract available
    
    
    
92. MAGGI P, Calo F, Messina V, Stornaiuolo G, et al
    Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis.
    PLoS One. 2022;17:e0265178.
    PubMed     Abstract available
    
    
    
93. KIMER N, Meldgaard M, Hamberg O, Kronborg TM, et al
    The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.
    PLoS One. 2022;17:e0264278.
    PubMed     Abstract available
    
    
    
94. CHOI SI, Cho Y, Ki M, Kim BH, et al
    Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.
    PLoS One. 2022;17:e0265668.
    PubMed     Abstract available
    
    
    
95. REINHARDT B, Taylor R, Dawkins C, Banks T, et al
    The use of dried blood spot cards to assess serologic responses of individuals vaccinated against measles, hepatitis A, tetanus, influenza and varicella zoster.
    PLoS One. 2022;17:e0265813.
    PubMed     Abstract available
    
    
    
96. YAZDANI K, Dolguikh K, Zhang W, Shayegi-Nik S, et al
    Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
    PLoS One. 2022;17:e0265811.
    PubMed     Abstract available
    
    
    
97. TANA MM, Klepper A, Lyden A, Pisco AO, et al
    Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.
    PLoS One. 2022;17:e0264307.
    PubMed     Abstract available
    
    
    
98. BURDETTE DL, Lazerwith S, Yang J, Chan HLY, et al
    Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
    PLoS One. 2022;17:e0262516.
    PubMed     Abstract available
    
    
    
99. 
    Expression of Concern: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.
    PLoS One. 2022;17:e0266498.
    PubMed    
    
    
    
100. 
     Expression of Concern: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-gamma Signaling in IFN-alpha Resistant HCV Replicon Cells.
     PLoS One. 2022;17:e0266497.
     PubMed    
     
     
     
101. CHANDRA DEB L, Hove H, Miller TK, Pinks K, et al
     Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota.
     PLoS One. 2022;17:e0266047.
     PubMed     Abstract available
     
     
     
102. XIA Z, Qin L, Ning Z, Zhang X, et al
     Deep learning time series prediction models in surveillance data of hepatitis incidence in China.
     PLoS One. 2022;17:e0265660.
     PubMed     Abstract available
     
     
     
103. THI CAM HUONG N, Trung NQ, Luong BA, Tram DB, et al
     Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients.
     PLoS One. 2022;17:e0266134.
     PubMed     Abstract available
     
     
     
104. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
     Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
     PLoS One. 2022;17:e0261069.
     PubMed     Abstract available
     
     
     
105. SEYOUM E, Demissie M, Worku A, Mulu A, et al
     HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study.
     PLoS One. 2022;17:e0267230.
     PubMed     Abstract available
     
     
     
106. AUMA AWN, Kowal C, Shive CL, Lange A, et al
     Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
     PLoS One. 2022;17:e0267512.
     PubMed     Abstract available
     
     
     
107. MABUNDA N, Augusto O, Zicai AF, Duaja A, et al
     Nucleic acid testing identifies high prevalence of blood borne viruses among approved blood donors in Mozambique.
     PLoS One. 2022;17:e0267472.
     PubMed     Abstract available
     
     
     
108. FACENTE SN, Grinstein R, Bruhn R, Kaidarova Z, et al
     Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
     PLoS One. 2022;17:e0267902.
     PubMed     Abstract available
     
     
     
109. MANZOOR S, Khalid M, Idrees M
     P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcripts; in presence of replicating HCV in in vitro setting: An insight into role of P2X4 in fibrosis.
     PLoS One. 2022;17:e0259727.
     PubMed     Abstract available
     
     
     
110. SSEKAMATTE T, Isunju JB, Mutyoba JN, Tetui M, et al
     Predictors of Hepatitis B screening and vaccination status of young psychoactive substance users in informal settlements in Kampala, Uganda.
     PLoS One. 2022;17:e0267953.
     PubMed     Abstract available
     
     
     
111. GUZMAN-HOLST A, Luna-Casas G, Burguete Garcia A, Madrid-Marina V, et al
     Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study.
     PLoS One. 2022;17:e0268469.
     PubMed     Abstract available
     
     
     
112. BATSAIKHAN B, Huang CI, Yeh ML, Huang CF, et al
     Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.
     PLoS One. 2022;17:e0268180.
     PubMed     Abstract available
     
     
     
113. O'DONNELL A, Pham N, Battisti L, Epstein R, et al
     Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.
     PLoS One. 2022;17:e0268478.
     PubMed     Abstract available
     
     
     
114. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
     Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
     PLoS One. 2022;17:e0267853.
     PubMed     Abstract available
     
     
     
115. ULLAH A, Yu X, Odenthal M, Meemboor S, et al
     Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.
     PLoS One. 2022;17:e0268526.
     PubMed     Abstract available
     
     
     
116. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
     Correction: Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
     PLoS One. 2022;17:e0269049.
     PubMed     Abstract available
     
     
     
117. FERNANDEZ VILLALOBOS NV, Kessel B, Rodiah I, Ott JJ, et al
     Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis.
     PLoS One. 2022;17:e0269253.
     PubMed     Abstract available
     
     
     
118. KENFACK-MOMO R, Kenmoe S, Takuissu GR, Ebogo-Belobo JT, et al
     Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.
     PLoS One. 2022;17:e0269250.
     PubMed     Abstract available
     
     
     
119. DIAMOND T, Burn TN, Nishiguchi MA, Minichino D, et al
     Familial hemophagocytic lymphohistiocytosis hepatitis is mediated by IFN-gamma in a predominantly hepatic-intrinsic manner.
     PLoS One. 2022;17:e0269553.
     PubMed     Abstract available
     
     
     
120. CHUAYPEN N, Siripongsakun S, Hiranrat P, Tanpowpong N, et al
     Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
     PLoS One. 2022;17:e0269641.
     PubMed     Abstract available
     
     
     
121. MADEIRA F, Costa-Lopes R, Do Bu EA, Tato Marinho R, et al
     The role of stereotypical information on medical judgements for black and white patients.
     PLoS One. 2022;17:e0268888.
     PubMed     Abstract available
     
     
     
122. SIEDLECKA M, Kublicka A, Wieliczko A, Matczuk AK, et al
     Molecular detection of avian hepatitis E virus (Orthohepevirus B) in chickens, ducks, geese, and western capercaillies in Poland.
     PLoS One. 2022;17:e0269854.
     PubMed     Abstract available
     
     
     
123. ISUNJU JB, Wafula ST, Ndejjo R, Nuwematsiko R, et al
     Awareness of hepatitis B post-exposure prophylaxis among healthcare providers in Wakiso district, Central Uganda.
     PLoS One. 2022;17:e0270181.
     PubMed     Abstract available
     
     
     
124. RAU M, Buggisch P, Mauss S, Boeker KHW, et al
     Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
     PLoS One. 2022;17:e0264741.
     PubMed     Abstract available
     
     
     
125. SONO S, Sae-Chan J, Kaewdech A, Chamroonkul N, et al
     HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program.
     PLoS One. 2022;17:e0270458.
     PubMed     Abstract available
     
     
     
126. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
     Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
     PLoS One. 2022;17:e0271197.
     PubMed     Abstract available
     
     
     
127. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
     The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
     PLoS One. 2022;17:e0270911.
     PubMed     Abstract available
     
     
     
128. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
     Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
     PLoS One. 2022;17:e0271020.
     PubMed     Abstract available
     
     
     
129. WOO HY, Heo J, Tak WY, Lee HJ, et al
     Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial.
     PLoS One. 2022;17:e0270716.
     PubMed     Abstract available
     
     
     
130. WANG CH, Lin RC, Hsu HY, Tseng YT, et al
     Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study.
     PLoS One. 2022;17:e0271790.
     PubMed     Abstract available
     
     
     
131. SAHIBZADA KI, Ganova-Raeva L, Dimitrova Z, Ramachandran S, et al
     Hepatitis C virus transmission cluster among injection drug users in Pakistan.
     PLoS One. 2022;17:e0270910.
     PubMed     Abstract available
     
     
     
132. MATA-MARIN JA, de Pablos-Leal AA, Mauss S, Arroyo-Anduiza CI, et al
     Risk factors for HCV transmission in HIV-positive men who have sex with men in Mexico.
     PLoS One. 2022;17:e0269977.
     PubMed     Abstract available
     
     
     
133. WAHOME PK, Kiende P, Nakazea RJ, Mwasowa NM, et al
     Occult hepatitis B virus infections and risk factors among school-going adolescent voluntary blood donors in Kwale County Kenya, January 2020-June 2021: Cross sectional study.
     PLoS One. 2022;17:e0263473.
     PubMed     Abstract available
     
     
     
134. LAHOOD A, Rahman R, McKenna L, Frick M, et al
     Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.
     PLoS One. 2022;17:e0271102.
     PubMed     Abstract available
     
     
     
135. PISANO MB, Campbell C, Anugwom C, Re VE, et al
     Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays.
     PLoS One. 2022;17:e0272809.
     PubMed     Abstract available
     
     
     
136. VAKILI J, Sizemore L, Rebeiro PF, Tyndall B, et al
     Assessment of Tennessee's county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators.
     PLoS One. 2022;17:e0270891.
     PubMed     Abstract available
     
     
     
137. HYRINA A, Burdette D, Song Z, Ramirez R, et al
     Targeting lipid biosynthesis pathways for hepatitis B virus cure.
     PLoS One. 2022;17:e0270273.
     PubMed     Abstract available
     
     
     
138. SCHORR O, Blach S, Thurnheer C, Ruis C, et al
     Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
     PLoS One. 2022;17:e0272518.
     PubMed     Abstract available
     
     
     
139. LU YH, Lu CK, Chen CH, Hsieh YY, et al
     Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
     PLoS One. 2022;17:e0272567.
     PubMed     Abstract available
     
     
     
140. TESFU MA, Belay NB, Habtemariam TT
     Co-infection of HIV or HCV among HBsAg positive delivering mothers and its associated factors in governmental hospitals in Addis Ababa, Ethiopia: A cross-sectional study.
     PLoS One. 2022;17:e0273300.
     PubMed     Abstract available
     
     
     
141. STOPKA TJ, Yaghi O, Li M, Paintsil E, et al
     Molecular and spatial epidemiology of HCV among people who inject drugs in Boston, Massachusetts.
     PLoS One. 2022;17:e0266216.
     PubMed     Abstract available
     
     
     
142. KHALID FK, Rasheed NA, Hussein NR, Naqid IA, et al
     A study of HBV infection and its risk factors in pregnant women in Zakho city, Iraq.
     PLoS One. 2022;17:e0273362.
     PubMed     Abstract available
     
     
     
143. TAKUISSU GR, Kenmoe S, Amougou Atsama M, Atenguena Okobalemba E, et al
     Global epidemiology of occult hepatitis B virus infections in blood donors, a systematic review and meta-analysis.
     PLoS One. 2022;17:e0272920.
     PubMed     Abstract available
     
     
     
144. CELESTE-VILLALVIR A, Wilkerson JM, Markham C, Rodriguez L, et al
     A qualitative investigation of organizational challenges and facilitators to screening individuals experiencing homelessness for hepatitis C virus (HCV) in Houston, Texas.
     PLoS One. 2022;17:e0273302.
     PubMed     Abstract available
     
     
     
145. BEHMARD E, Abdulabbas HT, Abdalkareem Jasim S, Najafipour S, et al
     Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach.
     PLoS One. 2022;17:e0272582.
     PubMed     Abstract available
     
     
     
146. NARTEY YA, Antwi SO, Bockarie AS, Hiebert L, et al
     Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.
     PLoS One. 2022;17:e0274544.
     PubMed     Abstract available
     
     
     
147. KACEM M, Dhouib W, Bennasrallah C, Zemni I, et al
     Occupational exposure to hepatitis C virus infection and associated factors among healthcare workers in Fattouma Bourguiba University Hospital, Tunisia.
     PLoS One. 2022;17:e0274609.
     PubMed     Abstract available
     
     
     
148. YOKOKAWA H, Shinohara M, Teraoka Y, Imamura M, et al
     Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
     PLoS One. 2022;17:e0274283.
     PubMed     Abstract available
     
     
     
149. WANG P, Zhang L, He J, Zhang G, et al
     Accuracy of hepatitis B disease surveillance, Gannan prefecture, Gansu province, China; 2017.
     PLoS One. 2022;17:e0274798.
     PubMed     Abstract available
     
     
     
150. HEREDIA JE, Sorenson C, Flanagan S, Nunez V, et al
     IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
     PLoS One. 2022;17:e0274582.
     PubMed     Abstract available
     
     
     
151. LEE AW, Jacobs W, Tran M, Nguyen B, et al
     Sociodemographic characteristics associated with hepatitis C virus infection in Vietnamese Americans: A cross-sectional analysis of community screening data.
     PLoS One. 2022;17:e0275210.
     PubMed     Abstract available
     
     
     
152. MABUNDA N, Vieira L, Chelene I, Maueia C, et al
     Prevalence of hepatitis B virus and immunity status among healthcare workers in Beira City, Mozambique.
     PLoS One. 2022;17:e0276283.
     PubMed     Abstract available
     
     
     
153. IBRAHIM ST, Abdelhamid MR, Lewis N, Baddour N, et al
     Role of fluid-phase complement system regulation in the development of hepatitis C virus-associated glomerulonephritis.
     PLoS One. 2022;17:e0276017.
     PubMed     Abstract available
     
     
     
154. EL SHEREF SEDM, Afify S, Berengy MS
     Clinical characteristics and predictors of esophagogastric variceal bleeding among patients with HCV-induced liver cirrhosis: An observational comparative study.
     PLoS One. 2022;17:e0275373.
     PubMed     Abstract available
     
     
     
155. BADSHAH Y, Shabbir M, Khan K, Fatima M, et al
     Manipulation of Interleukin-6 (IL-6) and Transforming Growth Factor Beta-1(TGFbeta-1) towards viral induced liver cancer pathogenesis.
     PLoS One. 2022;17:e0275834.
     PubMed     Abstract available
     
     
     
156. YAMATAKA K, Chu PS, Koda Y, Taniki N, et al
     Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.
     PLoS One. 2022;17:e0276925.
     PubMed     Abstract available
     
     
     
157. CHIA CT, Bender AT, Lillis L, Sullivan BP, et al
     Rapid detection of hepatitis C virus using recombinase polymerase amplification.
     PLoS One. 2022;17:e0276582.
     PubMed     Abstract available
     
     
     
158. OTHMAN B, Barakat M, Omar A, Al-Rawashdeh A, et al
     Evaluation of hepatitis B knowledge, practices, and beliefs among the Jordanian population: A cross-sectional study.
     PLoS One. 2022;17:e0277186.
     PubMed     Abstract available
     
     
     
159. YEE LM, Shah SK, Grobman WA, Labellarte PZ, et al
     Identifying barriers and facilitators of the inclusion of pregnant individuals in hepatitis C treatment programs in the United States.
     PLoS One. 2022;17:e0277987.
     PubMed     Abstract available
     
     
     
160. PRONIER C, Bomo J, Besombes J, Genet V, et al
     Characterization of hepatitis B viral forms from patient plasma using velocity gradient: Evidence for an excess of capsids in fractions enriched in Dane particles.
     PLoS One. 2022;17:e0272474.
     PubMed     Abstract available
     
     
     
161. DAGNEW M, Moges F, Tiruneh M, Million Y, et al
     Molecular diversity of hepatitis B virus among pregnant women in Amhara National Regional State, Ethiopia.
     PLoS One. 2022;17:e0276687.
     PubMed     Abstract available
     
     
     
162. ABU EL-MAKAREM MA, Kamel MF, Mohamed AA, Ali HA, et al
     Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.
     PLoS One. 2022;17:e0277266.
     PubMed     Abstract available
     
     
     
163. DABROWSKA-LEONIK N, Sawicka-Powierza J, Bernatowska E, Pac M, et al
     Lack of relationship between 25-hydoxyvitamin D concentration and a titer of antibodies to hepatitis B surface antigen in children under 12 years of age.
     PLoS One. 2022;17:e0277473.
     PubMed     Abstract available
     
     
     
164. NAGUIB M, Abdel-Razek W, Estaphan S, Abdelsameea E, et al
     Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C.
     PLoS One. 2022;17:e0276592.
     PubMed     Abstract available
     
     
     
165. ANNISON L, Hackman H, Eshun PF, Annison S, et al
     Seroprevalence and effect of HBV and HCV co-infections on the immuno-virologic responses of adult HIV-infected persons on anti-retroviral therapy.
     PLoS One. 2022;17:e0278037.
     PubMed     Abstract available
     
     
     
166. DE GOIS JG, Guedes SJKO, Vieira AP, Follador FAC, et al
     Seroprevalence and factors associated with hepatitis B virus exposure in the incarcerated population from southern Brazil.
     PLoS One. 2022;17:e0278029.
     PubMed     Abstract available
     
     
     
167. DEMA E, Stander J, Cortina-Borja M, Thorne C, et al
     Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling.
     PLoS One. 2022;17:e0274389.
     PubMed     Abstract available
     
     
     
168. ESTEBAN R, Dominguez-Hernandez R, Martin-Escudero V, Casado MA, et al
     Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.
     PLoS One. 2022;17:e0278544.
     PubMed     Abstract available
     
     
     
169. MASESE LN, Ludwig-Barron NT, Mbogo L, Guthrie BL, et al
     Occupational roles and risks of community-embedded peer educators providing HIV, hepatitis C and harm reduction services to persons who inject drugs in Nairobi, Kenya.
     PLoS One. 2022;17:e0278210.
     PubMed     Abstract available
     
     
     
170. PALOMO-PINON S, Antonio-Villa NE, Garcia-Cortes LR, Rojano-Mejia D, et al
     Prevalent coinfection and associated factors for Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus in patients submitted to renal replacement therapy: A cross-sectional study of 21 dialysis units in the State of Mexico.
     PLoS One. 2022;17:e0275238.
     PubMed     Abstract available
     
     
     
171. ANANCHUENSOOK P, Suksawatamnauy S, Thaimai P, Sriphoosanaphan S, et al
     The association between vitamin D receptor polymorphism and phases of chronic hepatitis B infection in HBV carriers in Thailand.
     PLoS One. 2022;17:e0277907.
     PubMed     Abstract available
     
     
     
172. GILMORE SA, Tam D, Cheung TL, Snyder C, et al
     Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
     PLoS One. 2022;17:e0271145.
     PubMed     Abstract available
     
     
     
173. GOUTZAMANIS S, Doyle JS, Horyniak D, Higgs P, et al
     "Like a pickle that's been unpickled": Emotional, identity and behavioural transformations throughout hepatitis C treatment.
     PLoS One. 2022;17:e0272401.
     PubMed     Abstract available
     
     
     
174. SHIRAI K, Hikita H, Sakamori R, Doi A, et al
     Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
     PLoS One. 2022;17:e0279416.
     PubMed     Abstract available
     
     
     
175. MARCELINO R, Ezeonwumelu IJ, Janeiro A, Mimoso P, et al
     Phylogeography of hepatitis B virus: The role of Portugal in the early dissemination of HBV worldwide.
     PLoS One. 2022;17:e0276618.
     PubMed     Abstract available
     
     
     
176. MIYANO S, Pathammavong C, Ichimura Y, Sugiyama M, et al
     Prevalence of hepatitis B and C virus infections in Lao People's Democratic Republic: The first national population-based cross-sectional survey.
     PLoS One. 2022;17:e0278933.
     PubMed     Abstract available
     
     
     
177. BEDASSA BB, Ebo GG, Yimam JA, Tura JB, et al
     Prevalence and factors associated with hepatitis B and C virus infections among female Sex workers in Ethiopia: Results of the national biobehavioral Survey, 2020.
     PLoS One. 2022;17:e0269510.
     PubMed     Abstract available
     
     
     January 2021
178. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
     Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
     PLoS One. 2021;16:e0249701.
     PubMed     Abstract available
     
     
     
179. 
     Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
     PLoS One. 2021;16:e0250185.
     PubMed     Abstract available
     
     
     
180. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
     Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
     PLoS One. 2021;16:e0249585.
     PubMed     Abstract available
     
     
     
181. KASHIWAKURA JI, Saitoh K, Ihara T, Sasaki Y, et al
     Correction: Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
     PLoS One. 2021;16:e0250536.
     PubMed     Abstract available
     
     
     
182. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
     Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
     PLoS One. 2021;16:e0249770.
     PubMed     Abstract available
     
     
     
183. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
     Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
     PLoS One. 2021;16:e0250263.
     PubMed     Abstract available
     
     
     
184. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
     Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
     PLoS One. 2021;16:e0249836.
     PubMed     Abstract available
     
     
     
185. ANTENEH ZA, Wondaye E, Mengesha EW
     Hepatitis B virus infection and its determinants among HIV positive pregnant women: Multicenter unmatched case-control study.
     PLoS One. 2021;16:e0251084.
     PubMed     Abstract available
     
     
     
186. VIEIRA BARBOSA J, Sahli R, Aubert V, Chaouch A, et al
     Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
     PLoS One. 2021;16:e0250347.
     PubMed     Abstract available
     
     
     
187. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
     Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
     PLoS One. 2021;16:e0251392.
     PubMed     Abstract available
     
     
     
188. 
     Correction: Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
     PLoS One. 2021;16:e0251539.
     PubMed     Abstract available
     
     
     
189. LEE CY, Wu PH, Lu MW, Chen TC, et al
     High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
     PLoS One. 2021;16:e0251158.
     PubMed     Abstract available
     
     
     
190. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
     Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
     PLoS One. 2021;16:e0250833.
     PubMed     Abstract available
     
     
     
191. CHA HJ, Hwang J, Lee LE, Park Y, et al
     The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
     PLoS One. 2021;16:e0244950.
     PubMed     Abstract available
     
     
     
192. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
     Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
     PLoS One. 2021;16:e0251673.
     PubMed     Abstract available
     
     
     
193. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
     The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
     PLoS One. 2021;16:e0251934.
     PubMed     Abstract available
     
     
     
194. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
     Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
     PLoS One. 2021;16:e0252490.
     PubMed     Abstract available
     
     
     
195. MALAMBA SS, Muyinda H, Ogwang DM, Katamba A, et al
     Cango Lyec (Healing the Elephant): Chronic Hepatitis B Virus among post-conflict affected populations living in mid-Northern Uganda.
     PLoS One. 2021;16:e0251573.
     PubMed     Abstract available
     
     
     
196. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
     "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
     PLoS One. 2021;16:e0250901.
     PubMed     Abstract available
     
     
     
197. PARK JS, Wong J, Cohen H
     Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
     PLoS One. 2021;16:e0252976.
     PubMed     Abstract available
     
     
     
198. WYNN A, Tweeten S, McDonald E, Wooten W, et al
     The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
     PLoS One. 2021;16:e0251635.
     PubMed     Abstract available
     
     
     
199. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
     HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
     PLoS One. 2021;16:e0252412.
     PubMed     Abstract available
     
     
     
200. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
     Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
     PLoS One. 2021;16:e0253710.
     PubMed     Abstract available
     
     
     
201. RASTOGI A, Chauhan S, Ramalingam A, Verma M, et al
     Capacity building of healthcare workers: Key step towards elimination of viral hepatitis in developing countries.
     PLoS One. 2021;16:e0253539.
     PubMed     Abstract available
     
     
     
202. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
     Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
     PLoS One. 2021;16:e0253470.
     PubMed     Abstract available
     
     
     
203. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
     Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
     PLoS One. 2021;16:e0253005.
     PubMed     Abstract available
     
     
     
204. ADANE T, Getawa S
     The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
     PLoS One. 2021;16:e0251570.
     PubMed     Abstract available
     
     
     
205. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
     Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
     PLoS One. 2021;16:e0254028.
     PubMed     Abstract available
     
     
     
206. GOMES LC, Sanson MCG, Brainin P, de Melo MDCV, et al
     Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon.
     PLoS One. 2021;16:e0253752.
     PubMed     Abstract available
     
     
     
207. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
     Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
     PLoS One. 2021;16:e0254243.
     PubMed     Abstract available
     
     
     
208. HOA TN, Munshi SU, Ngoc KN, Ngoc CL, et al
     A tightly clustered hepatitis E virus genotype 1a is associated with endemic and outbreak infections in Bangladesh.
     PLoS One. 2021;16:e0255054.
     PubMed     Abstract available
     
     
     
209. BLOOM DE, Khoury A, Srinivasan V
     Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
     PLoS One. 2021;16:e0252764.
     PubMed     Abstract available
     
     
     
210. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
     Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
     PLoS One. 2021;16:e0255336.
     PubMed     Abstract available
     
     
     
211. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
     Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
     PLoS One. 2021;16:e0255173.
     PubMed     Abstract available
     
     
     
212. JOSHUA PE, Nwauzor CO, Odimegwu DC, Ukachukwu UG, et al
     Experimental and molecular predictions of the adjuvanticity of snail mucin on hepatitis B vaccine in albino mice.
     PLoS One. 2021;16:e0246915.
     PubMed     Abstract available
     
     
     
213. RUTHERFORD L, Stark A, Ablona A, Klassen BJ, et al
     Health and well-being of trans and non-binary participants in a community-based survey of gay, bisexual, and queer men, and non-binary and Two-Spirit people across Canada.
     PLoS One. 2021;16:e0246525.
     PubMed     Abstract available
     
     
     
214. ERIKSEN LL, Nielsen MA, Laursen TL, Deleuran B, et al
     Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis.
     PLoS One. 2021;16:e0255574.
     PubMed     Abstract available
     
     
     
215. SINN DH, Kang D, Hong YS, Koh KC, et al
     Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
     PLoS One. 2021;16:e0255624.
     PubMed     Abstract available
     
     
     
216. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
     Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
     PLoS One. 2021;16:e0256164.
     PubMed     Abstract available
     
     
     
217. ISRAR M, Ali F, Nawaz A, Idrees M, et al
     Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan.
     PLoS One. 2021;16:e0255189.
     PubMed     Abstract available
     
     
     
218. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
     Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
     PLoS One. 2021;16:e0256816.
     PubMed     Abstract available
     
     
     
219. HEFZY EM, Hassuna NA, Shaker OG, Masoud M, et al
     miR-155 T/A (rs767649) and miR-146a A/G (rs57095329) single nucleotide polymorphisms as risk factors for chronic hepatitis B virus infection among Egyptian patients.
     PLoS One. 2021;16:e0256724.
     PubMed     Abstract available
     
     
     
220. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
     Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
     PLoS One. 2021;16:e0256711.
     PubMed     Abstract available
     
     
     
221. CHEN YC, Li CH, Ko PH, Lee CC, et al
     Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
     PLoS One. 2021;16:e0256505.
     PubMed     Abstract available
     
     
     
222. OSAMUDIAMEN FT, Akanbi OA, Oluwayelu DO, Bock CT, et al
     Serological evidence of avian HEV antibodies in apparently healthy chickens in southwest Nigeria.
     PLoS One. 2021;16:e0247889.
     PubMed     Abstract available
     
     
     
223. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
     A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
     PLoS One. 2021;16:e0257166.
     PubMed     Abstract available
     
     
     
224. GHOSH A, Onsager C, Mason A, Arriola L, et al
     The role of oxygen intake and liver enzyme on the dynamics of damaged hepatocytes: Implications to ischaemic liver injury via a mathematical model.
     PLoS One. 2021;16:e0230833.
     PubMed     Abstract available
     
     
     
225. HAILE K, Timerga A, Mose A, Mekonnen Z, et al
     Hepatitis B vaccination status and associated factors among students of medicine and health sciences in Wolkite University, Southwest Ethiopia: A cross-sectional study.
     PLoS One. 2021;16:e0257621.
     PubMed     Abstract available
     
     
     
226. QUAYE T, Narkwa PW, Domfeh SA, Kattah G, et al
     Immunosurveillance and molecular detection of hepatitis B virus infection amongst vaccinated children in the West Gonja District in Savanna Region of Ghana.
     PLoS One. 2021;16:e0257103.
     PubMed     Abstract available
     
     
     
227. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
     Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
     PLoS One. 2021;16:e0257369.
     PubMed     Abstract available
     
     
     
228. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
     Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
     PLoS One. 2021;16:e0249556.
     PubMed     Abstract available
     
     
     
229. KONG L, Karns R, Shata MTM, Brown JL, et al
     The synthetic opioid fentanyl enhances viral replication in vitro.
     PLoS One. 2021;16:e0249581.
     PubMed     Abstract available
     
     
     
230. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
     Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
     PLoS One. 2021;16:e0249435.
     PubMed     Abstract available
     
     
     
231. LEE SO, Lee JE, Lee S, Lee SH, et al
     Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
     PLoS One. 2021;16:e0249361.
     PubMed     Abstract available
     
     
     
232. MAZHAR MKA, Finger F, Evers ES, Kuehne A, et al
     An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox's Bazar, Bangladesh: Findings from enhanced epidemiological surveillance.
     PLoS One. 2021;16:e0250505.
     PubMed     Abstract available
     
     
     
233. AFANEH H, Straif-Bourgeois S, Oral E, Wennerstrom A, et al
     Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.
     PLoS One. 2021;16:e0257437.
     PubMed     Abstract available
     
     
     
234. KANG SH, Cho DH, Choi J, Baik SK, et al
     Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
     PLoS One. 2021;16:e0258229.
     PubMed     Abstract available
     
     
     
235. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
     The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
     PLoS One. 2021;16:e0258143.
     PubMed     Abstract available
     
     
     
236. BALEGHA AN, Yidana A, Abiiro GA
     Knowledge, attitude and practice of hepatitis B infection prevention among nursing students in the Upper West Region of Ghana: A cross-sectional study.
     PLoS One. 2021;16:e0258757.
     PubMed     Abstract available
     
     
     
237. ELKARANSHAWY HA, Ezzat HM, Ibrahim NN
     Lyapunov function and global asymptotic stability for a new multiscale viral dynamics model incorporating the immune system response: Implemented upon HCV.
     PLoS One. 2021;16:e0257975.
     PubMed     Abstract available
     
     
     
238. KAMALI I, Barnhart DA, Ndahimana JD, Noor K, et al
     Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: A cross-sectional study.
     PLoS One. 2021;16:e0257917.
     PubMed     Abstract available
     
     
     
239. PEDARRIEU A, El Mellouli F, Khallouki H, Zro K, et al
     External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions.
     PLoS One. 2021;16:e0251263.
     PubMed     Abstract available
     
     
     
240. MREMI A, Yahaya JJ, Nyindo M, Mollel E, et al
     Transfusion-Transmitted Infections and associated risk factors at the Northern Zone Blood Transfusion Center in Tanzania: A study of blood donors between 2017 and 2019.
     PLoS One. 2021;16:e0249061.
     PubMed     Abstract available
     
     
     
241. OLAKUNDE BO, Adeyinka DA, Olakunde OA, Uthman OA, et al
     A systematic review and meta-analysis of the prevalence of hepatitis B virus infection among pregnant women in Nigeria.
     PLoS One. 2021;16:e0259218.
     PubMed     Abstract available
     
     
     
242. KLOK S, van Dulm E, Boyd A, Generaal E, et al
     Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
     PLoS One. 2021;16:e0258932.
     PubMed     Abstract available
     
     
     
243. PAN CQ, Chang TT, Bae SH, Brunetto M, et al
     Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
     PLoS One. 2021;16:e0251552.
     PubMed     Abstract available
     
     
     
244. FERRETO LED, Guedes SJKO, Pauli FB, Rovani SS, et al
     Correction: Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
     PLoS One. 2021;16:e0260179.
     PubMed     Abstract available
     
     
     
245. STEPHENS Z, O'Brien D, Dehankar M, Roberts LR, et al
     Exogene: A performant workflow for detecting viral integrations from paired-end next-generation sequencing data.
     PLoS One. 2021;16:e0250915.
     PubMed     Abstract available
     
     
     
246. DUAH A, Agyei-Nkansah A, Osei-Poku F, Duah F, et al
     Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana.
     PLoS One. 2021;16:e0253759.
     PubMed     Abstract available
     
     
     
247. CASTRO LS, Rezende GR, Pires Fernandes FR, Bandeira LM, et al
     HAV infection in Brazilian men who have sex with men: The importance of surveillance to avoid outbreaks.
     PLoS One. 2021;16:e0256818.
     PubMed     Abstract available
     
     
     
248. TOWNSHEND-BULSON L, Roik E, Barbour Y, Bruden DJT, et al
     The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
     PLoS One. 2021;16:e0260970.
     PubMed     Abstract available
     
     
     
249. YU S, Chen W, Jiang Z
     Platelet count/spleen volume ratio has a good predictive value for esophageal varices in patients with hepatitis B liver cirrhosis.
     PLoS One. 2021;16:e0260774.
     PubMed     Abstract available
     
     
     
250. HERNANDEZ-SUAREZ G, Saha D, Lodrono K, Boonmahittisut P, et al
     Seroprevalence and incidence of hepatitis A in Southeast Asia: A systematic review.
     PLoS One. 2021;16:e0258659.
     PubMed     Abstract available
     
     
     
251. GUAN TH, Htut HN, Davison CM, Sebastian S, et al
     Implementation of a neonatal hepatitis B immunization program in rural Karenni State, Myanmar: A mixed-methods study.
     PLoS One. 2021;16:e0261470.
     PubMed     Abstract available
     
     
     
252. GARCIA-HEROLA A, Dominguez-Hernandez R, Casado MA
     Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.
     PLoS One. 2021;16:e0260608.
     PubMed     Abstract available
     
     
     
253. ABGHOUR S, Mouahid M, Darkaoui S, Berrada J, et al
     Pathogenicity of field strain of fowl aviadenovirus serotype 11 isolated from chickens with inclusion body hepatitis in Morocco.
     PLoS One. 2021;16:e0261284.
     PubMed     Abstract available
     
     
     
254. NERSESOV A, Gusmanov A, Crape B, Junusbekova G, et al
     Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan.
     PLoS One. 2021;16:e0261155.
     PubMed     Abstract available
     
     
     
255. BITTY-ANDERSON AM, Ferre V, Gbeasor-Komlanvi FA, Tchankoni MK, et al
     Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
     PLoS One. 2021;16:e0259891.
     PubMed     Abstract available
     
     
     
256. DE VOS CJ, Hennen WHGJ, van Roermund HJW, Dhollander S, et al
     Assessing the introduction risk of vector-borne animal diseases for the Netherlands using MINTRISK: A Model for INTegrated RISK assessment.
     PLoS One. 2021;16:e0259466.
     PubMed     Abstract available
     
     
     
257. SUZUKI T, Matsuura K, Nagura Y, Iio E, et al
     Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection.
     PLoS One. 2021;16:e0261878.
     PubMed     Abstract available
     
     
     
258. CHEN Q, Liu J, He Y, Yang L, et al
     Prevalence of HBsAg among reproductive age couples in Chongqing: A population-based, cross-sectional study.
     PLoS One. 2021;16:e0260028.
     PubMed     Abstract available
     
     
     
259. AZIT NA, Sahran S, Voon Meng L, Subramaniam M, et al
     Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.
     PLoS One. 2021;16:e0260675.
     PubMed     Abstract available
     
     
     
260. NOUANTHONG P, Hefele L, Keokhamphue J, Sorrasin V, et al
     Analyses of blood donor samples from eight provinces in Lao PDR suggest considerable variation concerning HBV exposure and carriage.
     PLoS One. 2021;16:e0259814.
     PubMed     Abstract available
     
     
     
261. SCHMIDBAUER C, Schwarz M, Schutz A, Schubert R, et al
     Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
     PLoS One. 2021;16:e0252274.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.